KCx Integrates Proprietary Data into FlexTrade’s AI Assistant, FlxAI
12.5.2025 10:04:00 CEST | Business Wire | Press release
New workflow, presented at TradeTech Europe in Paris, enables mutual clients seamless access to KCx analytics data through natural language queries in FlxAI, paving the way for future agent-to-agent communication
FlexTrade Systems, a global leader in multi-asset execution and order management systems, and Kepler Cheuvreux, a leading independent European financial services company through its KCx execution services, today announced the availability of KCx’s sophisticated analytical suite directly from FlexTrade’s AI assistant, FlxAI, to deliver intelligent, high-value insights into client workflows.
With rapid advancements in AI, large language models are reshaping how financial firms interact with data. Trading desks are increasingly embracing conversational AI to streamline decision-making and extract actionable insights faster than ever before. In response to market drivers, the new workflow has been developed as part of a collaborative initiative between KCx’s and FlexTrade’s teams.
Through the new collaboration, users of FlxAI, which is seamlessly embedded in FlexTrade's FlexONE OEMS and FlexTRADER EMS solutions, can actively query KCx liquidity drivers through natural language commands, such as "What's the anticipated closing volume according to KCx?" or "What does KCx think the volatility will be today?" FlxAI translates these requests into API commands, which are passed to KCx. KCx then returns the result, derived from vast streams of structured data — timestamps, prices, venues, order types — which FlxAI translates and presents to the end user within the order blotter as rich, human-readable narratives. These narratives explain factors such as slippage drivers, venue performance, and hidden cost patterns. Additionally, using AI, KCx’s analytics continuously learns from evolving market conditions, transforming the analytics feedback in real-time.
Further development from KCx will see their own AI chat agent launch, delivering additional proprietary data points and working order content to users directly. Through agent-to-agent communication, FlxAI will extend to this AI agent to provide answers to user questions determined to be directed to KCx.
Chris McConville, Global Head of Execution Services and Trading at KCx said: “Built on the foundation of our robust API Analytical Suite offering, this workflow integration represents a major step forward. KCx is introducing this new capability through FlexTrade, which aligns with our mission to provide accessible, high-value insights directly into our clients' workflows. Rather than only focusing on AI-driven execution algorithms, our priority is to enhance workflow efficiency — improving decision support, reducing manual processes, and simplifying interactions with complex data. This enables traders and portfolio managers to focus on more strategic, high-value tasks.”
Andy Mahoney, Managing Director, EMEA at FlexTrade, stated: “Our existing integration with KCx’s analytic suite has proved popular with clients looking to source high-quality, adaptive market intelligence. Integrating the KCx data source into FlxAI was a natural step to extend the coverage to third-party data, which is relevant, useful, and timely to users. As the sell-side finds new and unique ways to deliver content to clients, we aim to provide a seamless interface to access all services available. With FlxAI, connected to an abundance of data sources and other AI agents, this will ensure interaction is completely natural.”
Anvar Karimson, Chief Technology Officer, Kepler Cheuvreux, noted:“This innovative integration marks a significant technological advancement in delivering intelligence when traders need it most. By connecting KCx analytics with FlxAI, we're transforming how insights flow through decision workflows. Natural language interaction elegantly removes barriers between complex analysis and trading decisions. This reflects our core belief that sophisticated technology should feel intuitive while enhancing how clients interact with markets.”
KCx and FlexTrade will demonstrate this innovation at TradeTech Europe, May 13 - 15. The FlexTrade team will be in Track C during the roundtable sessions at the Buy-Side Innovation Day on May 13. Additionally, the innovation will be showcased at Booth 36 with the FlexTrade team or Booth 58 with the KCx team during the Main Conference on May 14 and 15.
About Kepler Cheuvreux:
Kepler Cheuvreux is a leading independent European financial services company that specialises in Research, Execution (KCx), Fixed Income and Credit, Structured Solutions, Corporate Finance, and Asset Management.
The group employs around 600 people and is present in 14 major financial centres in Europe, the US, and the Middle East: Amsterdam, Brussels, Dubai, Frankfurt, Geneva, London, Madrid, Milan, New York, Oslo, Paris, Stockholm, Vienna, and Zurich.
About FlexTrade:
FlexTrade Systems provides customized multi-asset execution and order management trading solutions for buy- and sell-side financial institutions. Through deep client partnerships with some of the world's largest, most complex, and demanding capital markets firms, we develop the flexible tools, technology, and innovation that give our clients a competitive edge. Our globally distributed engineering teams focus on adaptable technology and open architecture to develop highly sophisticated trading solutions that can automate and scale with your business strategies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250512589499/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom